[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20070194L - Fremgangsmater for behandling av hepatitt C - Google Patents

Fremgangsmater for behandling av hepatitt C

Info

Publication number
NO20070194L
NO20070194L NO20070194A NO20070194A NO20070194L NO 20070194 L NO20070194 L NO 20070194L NO 20070194 A NO20070194 A NO 20070194A NO 20070194 A NO20070194 A NO 20070194A NO 20070194 L NO20070194 L NO 20070194L
Authority
NO
Norway
Prior art keywords
treatment
hepatitis
methods
hcv
replication
Prior art date
Application number
NO20070194A
Other languages
English (en)
Inventor
Jeffrey Allen Campbell
Gary Mitchell Karp
Guangming Chen
Peter Seongwoo Hwang
James Takasugi
Hongyu Ren
Richard Gerald Wilde
Anthony Turpoff
Alexander Arefolov
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of NO20070194L publication Critical patent/NO20070194L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

I overensstemmelse med den foreliggende oppfinnelse er forbindelser som inhiberer viral replikasjon, foretrukket hepatitt C virus (HCV) replikasjon, blitt identifisert og fremgangsmåten for deres anvendelse er tilveiebragt. I et aspekt av oppfinnelsen er forbindelser som er anvendbare i behandling eller forebygging av en viral infeksjon tilveiebragt. I et annet aspekt av oppfinnelsen er forbindelser som er anvendbare i behandling eller forebygging av HCV infeksjon tilveiebragt.
NO20070194A 2004-07-14 2007-01-11 Fremgangsmater for behandling av hepatitt C NO20070194L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US58748704P 2004-07-14 2004-07-14
US63497904P 2004-12-13 2004-12-13
US64558605P 2005-01-24 2005-01-24
US66534905P 2005-03-28 2005-03-28
US67544005P 2005-04-28 2005-04-28
PCT/US2005/024881 WO2006019831A1 (en) 2004-07-14 2005-07-14 Methods for treating hepatitis c

Publications (1)

Publication Number Publication Date
NO20070194L true NO20070194L (no) 2007-04-16

Family

ID=35613725

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070194A NO20070194L (no) 2004-07-14 2007-01-11 Fremgangsmater for behandling av hepatitt C

Country Status (13)

Country Link
US (2) US8013006B2 (no)
EP (1) EP1771169A1 (no)
JP (1) JP2008506702A (no)
KR (1) KR20070083484A (no)
AU (1) AU2005275181A1 (no)
BR (1) BRPI0511834A (no)
CA (1) CA2573185A1 (no)
EA (1) EA200700243A1 (no)
EC (1) ECSP077252A (no)
IL (1) IL180645A0 (no)
MX (1) MX2007000481A (no)
NO (1) NO20070194L (no)
WO (1) WO2006019831A1 (no)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2007084413A2 (en) * 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005275181A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
NZ563909A (en) 2005-05-13 2011-10-28 Virochem Pharma Inc Thiophene derivatives and their use for the treatment or prevention of flavivirus infections
CN102304075A (zh) * 2005-10-11 2012-01-04 因特蒙公司 病毒复制抑制剂
RU2441010C2 (ru) * 2005-12-21 2012-01-27 Эбботт Лэборетриз Противовирусные соединения
PL2495016T3 (pl) * 2005-12-23 2020-06-01 Ariad Pharmaceuticals, Inc. Bicykliczne związki heteroarylowe
WO2007084435A2 (en) * 2006-01-13 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
CA2644389A1 (en) * 2006-03-03 2007-09-20 Schering Corporation Pharmaceutical combinations of hcv-protease and -ires inhibitors
BRPI0710328A2 (pt) 2006-05-08 2011-08-09 Ariad Pharma Inc composto da fórmula i, um tautomer da mesma, ou um sal farmaceuticamente aceitável, hidrato ou outro solvato do mesmo e método para o tratamento de cáncer em um mamìfero necessitado do mesmo e composição
SI3357911T1 (sl) 2006-06-26 2022-10-28 Akebia Therapeutics Inc. Inhibitorji prolil hidroksilaze in postopki uporabe
MX2009002921A (es) 2006-09-15 2009-04-01 Schering Corp Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
AP2009004840A0 (en) * 2006-10-13 2009-04-30 Xtl Biopharmaceuticals Ltd Compounds and methods for treatment of HCV
AP2579A (en) 2006-11-15 2013-01-29 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
KR100862113B1 (ko) 2007-01-22 2008-10-09 삼성전자주식회사 공정 변화에 대한 정보를 이용하여 공급전압/공급주파수를제어할 수 있는 장치와 방법
MX2009008439A (es) * 2007-02-12 2009-08-13 Intermune Inc Nuevos inhibidores de la replicacion del virus de hepatitis c.
JP5107589B2 (ja) * 2007-02-13 2012-12-26 旭化成株式会社 インドール誘導体
CN101815533A (zh) 2007-05-04 2010-08-25 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
MX2010001650A (es) * 2007-08-10 2010-08-02 Glaxosmithkline Llc Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales.
ES2592961T3 (es) * 2007-09-17 2016-12-02 Abbvie Bahamas Ltd. Pirimidinas antiinfecciosas y usos de las mismas
WO2009064852A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
US8367665B2 (en) 2008-04-16 2013-02-05 Karo Bio Ab Estrogen receptor ligands
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
PE20110368A1 (es) * 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
CN102300462B (zh) 2008-12-03 2015-01-28 普雷西迪奥制药公司 Hcv ns5a的抑制剂
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
WO2010118009A1 (en) * 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
US8841302B2 (en) 2009-04-06 2014-09-23 Ptc Therapeutics, Inc. HCV inhibitor and therapeutic agent combinations
US9198907B2 (en) 2009-04-06 2015-12-01 Ptc Therapeutics, Inc. Combinations of a HCV inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
NZ596144A (en) * 2009-04-06 2014-01-31 Ptc Therapeutics Inc Indole derivatives and methods for antiviral treatment
US8980920B2 (en) 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
WO2011068715A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
JP2013512246A (ja) 2009-11-25 2013-04-11 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
SG181614A1 (en) 2009-12-24 2012-07-30 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
CN102918049A (zh) 2010-03-09 2013-02-06 默沙东公司 稠合三环甲硅烷基化合物及其用于治疗病毒性疾病的方法
EP2545042A1 (en) * 2010-03-11 2013-01-16 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
EP2550268A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119858A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
CN103038237A (zh) 2010-03-24 2013-04-10 沃泰克斯药物股份有限公司 用于黄病毒感染治疗或预防的类似物
EP2550267A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2582717A2 (en) 2010-06-15 2013-04-24 Vertex Pharmaceuticals Incorporated Hcv ns5b polymerase mutants
MX2012014918A (es) 2010-06-28 2013-04-08 Vertex Pharma Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
JP6215052B2 (ja) 2010-06-28 2017-10-18 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 有害生物防除剤としての複素環化合物
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
AU2011314168A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
JP5731004B2 (ja) 2010-10-26 2015-06-10 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤
PT2658844T (pt) 2010-12-28 2017-01-24 Sanofi Sa Novos derivados de pirimidinas, sua preparação e utilização farmacêutica como inibidores de fosforilação de akt (pkb)
EP2696681B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
NO2686520T3 (no) 2011-06-06 2018-03-17
AU2012268400C1 (en) 2011-06-06 2016-12-22 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
TW201317223A (zh) 2011-07-26 2013-05-01 Vertex Pharma 噻吩化合物
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
CA3128846A1 (en) * 2012-07-27 2014-01-30 Sato Pharmaceutical Co. Ltd. Difluoromethylene compound
RU2015121347A (ru) 2012-11-05 2016-12-27 НЭНТ ХОЛДИНГЗ АйПИ, ЭлЭлСи Производные, содержащие циклическую сульфонамидную группу, в качестве ингибиторов сигнального пути hedgenog
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US9073946B2 (en) 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
EP2769723A1 (en) * 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
EP3007695B1 (en) 2013-06-13 2024-02-07 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
JP6071825B2 (ja) * 2013-09-20 2017-02-01 株式会社東芝 不揮発性記憶装置
EP3068758B1 (en) 2013-11-15 2021-09-08 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and their method of use
EP3076964A1 (en) 2013-12-05 2016-10-12 Karo Pharma AB Estrogen receptor beta agonists for use in treating mesothelioma
KR20160147010A (ko) * 2014-04-28 2016-12-21 지앙수 카니온 파마수티컬 씨오., 엘티디. 항엔테로바이러스71 티아디아졸리딘 유도체
EP3188730B1 (en) 2014-09-05 2019-05-01 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
US9828369B2 (en) 2014-09-05 2017-11-28 Merck Sharpe & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
WO2016036633A1 (en) 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
TW201632504A (zh) 2015-01-23 2016-09-16 阿克比治療有限公司 ２－（５－（３－氟苯基）－３－羥吡啶醯胺基）乙酸之固體形式、其組合物及其用途
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
IL305910A (en) 2015-04-01 2023-11-01 Akebia Therapeutics Inc Formulation of an oral administration form of }]5-)3-chlorophenyl(-3-hydroxypyridine-2-carbonyl[amino{acetic acid
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10442763B2 (en) 2015-05-14 2019-10-15 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and methods using same
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10280175B2 (en) 2016-02-02 2019-05-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
JP6904970B2 (ja) 2016-03-07 2021-07-21 エナンタ ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎抗ウイルス剤
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
AU2017277664A1 (en) 2016-06-10 2019-01-24 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
AU2017314083B2 (en) 2016-08-15 2020-12-10 Bayer Aktiengesellschaft Condensed bicyclic heterocycle derivatives as pest control agents
US11104690B2 (en) 2016-11-18 2021-08-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
RU2019117958A (ru) 2016-11-18 2020-12-18 Мерк Шарп И Доум Корп. Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2
IL272941B2 (en) 2017-08-28 2023-03-01 Enanta Pharm Inc Antiviral agents for viral hepatitis b
WO2019113175A1 (en) 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US10428070B2 (en) 2017-12-06 2019-10-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
CN111741958A (zh) 2018-02-21 2020-10-02 拜耳公司 作为害虫防治剂的稠合双环杂环衍生物
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
EP3790863A1 (en) 2018-05-09 2021-03-17 Akebia Therapeutics Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
EP3793546A4 (en) 2018-05-17 2021-12-08 The Wistar Institute CRYSTALLINE FORMS OF EBNA1-INHIBITOR AND METHOD OF MANUFACTURING AND USING THEREOF
KR20210065965A (ko) 2018-09-21 2021-06-04 이난타 파마슈티칼스, 인코포레이티드 항바이러스제로서 작용화된 헤테로사이클
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
WO2020106816A1 (en) 2018-11-21 2020-05-28 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
WO2021203007A1 (en) * 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Substituted 5-hydroxyindole compounds as modulators of alpha-1 antitrypsin
CN116924959A (zh) * 2022-03-30 2023-10-24 山东大学 一种hdac11亚型选择性抑制剂及其制备方法和应用

Family Cites Families (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3530825A1 (de) * 1985-08-29 1987-03-05 Boehringer Mannheim Gmbh Neue benzodipyrrole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DD258014A1 (de) 1987-03-02 1988-07-06 Univ Leipzig Verfahren zur herstellung von 4-oxo-3,4-dihydro-pyrido/3',2':4,5/-thieno/3,2-d/pyrimidin-2-carbonsaeurealkylestern
DD258016A1 (de) 1987-03-02 1988-07-06 Univ Leipzig Verfahren zur herstellung von 4-alkoxy-pyrido/3',2':4,5/thieno/3,2-d/pyrimidin-2-carbonsaeurealkylestern
DD258015A1 (de) 1987-03-02 1988-07-06 Univ Leipzig Verfahren zur herstellung von gegebenfalls in 7,8- bzw. 8,9-stellung cycloaliphatisch verbrueckten 4-alkoxy-pyrido-/3',2':4,5/thieno/3,2-d/pyrimidin-2-carbonsaeuren
US4788206A (en) * 1987-07-10 1988-11-29 Hoffmann-La Roche Inc. Pentadieneamides
US5072003A (en) * 1989-04-24 1991-12-10 Amoco Corporation Acid anhydrides and dianhydrides of disubstituted maleic anhydrides
US5166170A (en) 1989-07-03 1992-11-24 Hoechst-Roussel Pharmaceuticals Incorporated 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
US5034393A (en) 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
JPH03246540A (ja) 1989-11-07 1991-11-01 Fuji Photo Film Co Ltd 直接ポジカラー写真感光材料
JP2649980B2 (ja) 1989-11-27 1997-09-03 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US5120752A (en) 1989-12-28 1992-06-09 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
US5118695A (en) * 1990-08-06 1992-06-02 Eastman Kodak Company 1-hydroxyindole fungicides
IL99161A (en) 1990-08-17 1996-11-14 Takeda Chemical Industries Ltd History of guanidine A process for their preparation and preparations from pesticides that contain them
US5210092A (en) 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
PH31175A (en) 1990-10-31 1998-03-20 Squibb & Sons Inc Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives.
JP2651755B2 (ja) 1991-03-01 1997-09-10 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
US5190942A (en) * 1991-04-22 1993-03-02 E. R. Squibb & Sons, Inc. Benzoxazole and related heterocyclic substituted imidazole and benzimidazole derivatives
US5527819A (en) * 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
GB9201789D0 (en) 1992-01-28 1992-03-11 Fujisawa Pharmaceutical Co Heterocyclic derivatives
US5354759A (en) * 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
US5693643A (en) * 1991-09-16 1997-12-02 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
JPH05255089A (ja) 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
JP2963288B2 (ja) 1992-01-14 1999-10-18 株式会社海洋バイオテクノロジー研究所 水中有害付着生物防除剤
US5215980A (en) * 1992-01-17 1993-06-01 Merck & Co., Inc. 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
EP0558245A1 (en) 1992-02-25 1993-09-01 RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors
US5605896A (en) * 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
US5474994A (en) * 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5314898A (en) 1992-06-29 1994-05-24 Merck & Co., Inc. Aryl thiopyrano[4,3,2-cd]indoles as inhibitors of leukotriene biosynthesis
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5922857A (en) * 1992-09-28 1999-07-13 Chiron Corporation Methods and compositions for controlling translation of HCV proteins
DE69327536T2 (de) * 1992-10-14 2000-07-06 Merck & Co., Inc. Fibrinogenrezeptor-antagonisten
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
CZ286412B6 (en) 1993-03-31 2000-04-12 Merck & Co Inc Synergetic combination of compounds for treating AIDS, pharmaceutical preparation containing such synergetic combination and use of this synergetic combination for preparing pharmaceutical preparation
CA2121391A1 (en) 1993-04-28 1994-10-29 Atsuyuki Kojima Indoloylguanidine derivatives
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
DE4321030A1 (de) 1993-06-24 1995-01-05 Bayer Ag 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel
US5369120A (en) * 1993-07-28 1994-11-29 Warner-Lambert Company Pharmaceutical composition of 7-((substituted)amino-8-((substituted)carbonyl)-(methylamino)-1-oxasp iro(4,5)decanes and L-dopa
GB2282808A (en) 1993-10-14 1995-04-19 Merck & Co Inc 3-substituted heterocyclic indoles as inhibitors of HIV reverse transcriptase
GB2292149A (en) 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
US5502071A (en) 1994-08-19 1996-03-26 American Cyanamid Company Indoles as insecticides and acaricides
US5639906A (en) * 1994-10-11 1997-06-17 The United States Of America As Represented By The Department Of Health And Human Services Fluorescent and NMR sensitive pH indicators
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
CA2160600A1 (en) 1994-10-18 1996-04-19 Masahumi Kitano Indoloylguanidine derivatives
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
WO1996032379A1 (en) * 1995-04-10 1996-10-17 Fujisawa Pharmaceutical Co., Ltd. INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS
US6376529B1 (en) 1995-06-07 2002-04-23 Peng Cho Tang Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
CA2244189A1 (en) * 1996-01-22 1997-07-31 Fujisawa Pharmaceutical Co., Ltd. Thiazolylbenzofuran derivatives and pharmaceutical compositions containing them
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
DK0802183T3 (da) 1996-04-19 2002-02-04 American Home Prod Østrogenforbindelser
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5985910A (en) * 1996-04-19 1999-11-16 American Home Products Corporation 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
US5977090A (en) * 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US6384022B1 (en) * 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US6184235B1 (en) * 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
JP4056593B2 (ja) * 1996-08-26 2008-03-05 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド 染料混合物、その製造方法及びその用途
AU726374B2 (en) * 1997-03-05 2000-11-02 University Of Washington Novel screening methods to identify agents that selectively inhibit hepatitis C virus replication
US6335445B1 (en) * 1997-03-24 2002-01-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US6809088B2 (en) * 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US5922898A (en) * 1997-04-08 1999-07-13 Catalytica Pharmaceuticals, Inc. Process for preparing biaryl compounds
US6194599B1 (en) * 1997-04-08 2001-02-27 Catalytica, Inc. Process for preparing biaryl compounds
US6326392B1 (en) * 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
ZA9811672B (en) * 1997-12-19 2000-06-19 Lilly Co Eli Hypoglycemic imidazoline compounds.
US6506758B2 (en) * 1997-12-24 2003-01-14 Smithkline Beecham Laboratoires Pharmceutiques Indole derivatives useful A.O. for the treatment of osteoporosis
WO1999033831A1 (en) * 1997-12-26 1999-07-08 Takeda Chemical Industries, Ltd. Nitrogen-containing heterocyclic compounds, their production and use
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
EP1067128A4 (en) * 1998-04-01 2001-11-21 Ono Pharmaceutical Co CONDENSED THIOPHENE DERIVATIVES AND MEDICINES THAT CONTAIN THEM AS ACTIVE ACTIVE SUBSTANCES
US6221902B1 (en) * 1998-05-12 2001-04-24 American Home Products Corporation Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6358992B1 (en) * 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
US6685931B1 (en) * 1998-12-22 2004-02-03 Schering Corporation Treatment of hepatitis C virus infections with interleukin-10
US6265403B1 (en) * 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
EP1091748A2 (en) * 1999-04-12 2001-04-18 University of Madras A pharmaceutical formulation useful for the treatment of hepatitis b, hepatitis c and other viral infections of the liver and a process for its preparation
US20020169101A1 (en) * 1999-05-10 2002-11-14 Gonzalez Maria Isabel Treatment of sexual dysfunction
AU5319700A (en) 1999-06-02 2000-12-18 S. Mbua Ngale Efange Nicotine receptor ligands
US6683115B2 (en) * 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US20030176697A1 (en) * 1999-06-30 2003-09-18 The Regents Of The University Of California Method for preparing crambescidin core acid intermediates and their use for preparing crambescidin alkaloid analogs as therapeutic agents
US6380166B1 (en) * 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
MX228790B (es) 1999-09-17 2005-06-30 Millennium Pharm Inc Inhibidores del factor xa.
WO2001023390A2 (de) 1999-09-28 2001-04-05 Basf Aktiengesellschaft Azepinoindol-derivate, deren herstellung und anwendung
HUP0202263A3 (en) * 1999-12-27 2003-02-28 Japan Tobacco Inc Benzimidazole, indole and imidazo-pyridine derivatives and pharmaceutical compositions containing them
US6770666B2 (en) * 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
US20020169107A1 (en) * 2001-01-19 2002-11-14 Mallinckrodt Inc. Novel aromatic azides for type I phototherapy
AU2868601A (en) 2000-01-27 2001-08-07 Ribotargets Ltd Biaryl compounds, their preparation and their use in therapy
DE10005631A1 (de) 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginin-Mimetika als Faktor X¶a¶-Inhibitoren
CA2396504A1 (en) 2000-02-29 2001-09-07 Dupont Pharmaceuticals Company Inhibitors of hepatitis c virus ns3 protease
US7566765B2 (en) * 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
US7091240B2 (en) * 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
US20040087798A1 (en) 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
ES2325477T3 (es) 2000-03-31 2009-09-07 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indoles sustituidos por fenilo como antagonistas del receptor de histamina h3.
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
DE60129806T2 (de) 2000-04-28 2007-12-06 Asahi Kasei Pharma Corp. Neue bizyklische verbindungen
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
JP2002030069A (ja) 2000-07-17 2002-01-29 Japan Science & Technology Corp 縮合ピロール類の製造法
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
PT2264018E (pt) 2000-08-24 2015-06-03 Univ Pittsburgh Derivados de tioflavina para uso no diagnóstico da doença de alzheimer
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
AU2001290131B2 (en) 2000-09-29 2007-11-15 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
AU2001290134A1 (en) 2000-09-29 2002-04-08 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
WO2002036580A2 (en) 2000-10-31 2002-05-10 Lynn Bonham Benzoxazole lpaat- beta inhibitors and uses thereof
US20020193369A1 (en) 2000-11-02 2002-12-19 Markham Penelope N. Antifungal compounds and uses therefor
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
WO2002051805A1 (de) 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indol-derivate
TWI312779B (no) 2000-12-28 2009-08-01 Daiichi Seiyaku Co
EP1354884B1 (en) 2000-12-28 2007-10-10 Ono Pharmaceutical Co., Ltd. Cyclopenta[d]pyrazolo[1,5-a]pyrimidine compound as crf receptor antagonist
EP1351936A1 (en) 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
JP2005503998A (ja) 2001-01-29 2005-02-10 ユニバーシティ オブ コネチカット 受容体選択性のカンナビミメティックアミノアルキルインドール
WO2002060374A2 (en) 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
AU2002247208A1 (en) 2001-03-05 2002-09-19 Icos Corporation Selective pde3b inhibitors and use of the same in therapy
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
WO2002083134A1 (en) 2001-04-12 2002-10-24 Pharmacopeia, Inc. Aryl and biaryl piperidines used as mch antagonists
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
WO2002096426A1 (en) 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
EP1406889A2 (en) 2001-07-09 2004-04-14 Pharmacia Italia S.p.A. Interaction inhibitors of tcf-4 with beta-catenin
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) * 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
AU2002336462A1 (en) 2001-09-06 2003-03-24 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7053071B2 (en) 2001-11-30 2006-05-30 The Burnham Institute Induction of apoptosis in cancer cells
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
AU2002360763A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
AU2002357312A1 (en) 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
US6930070B2 (en) * 2002-01-28 2005-08-16 Univation Technologies, Llc Heterocyclic nitrogen-containing activators and catalyst systems for olefin polymerization
MXPA04006616A (es) 2002-01-28 2004-10-04 Ciba Sc Holding Ag Soluciones acuosas de tintes.
KR20040084896A (ko) 2002-02-06 2004-10-06 버텍스 파마슈티칼스 인코포레이티드 Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물
DE10209520A1 (de) * 2002-03-04 2003-09-25 4Sc Ag Neue Modulatoren von Kaliumkanälen
US20030220377A1 (en) * 2002-05-08 2003-11-27 Richard Chesworth Indole compounds and their use as estrogen agonists/antagonists
US7312214B2 (en) 2002-05-10 2007-12-25 Bristol-Myers Squibb Company 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors
US6690975B2 (en) * 2002-05-17 2004-02-10 Bistner Co., Ltd. Methods for treating hepatitis C
US7008958B2 (en) * 2002-05-21 2006-03-07 Bristol-Myers Squibb Company 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same
TW200400004A (en) 2002-05-22 2004-01-01 Novartis Ag Organic compounds
US6974870B2 (en) * 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
US20050244718A1 (en) 2002-07-01 2005-11-03 Eike Poetsch Polymerizable, luminescent compounds and mixtures, luminescent polymer materials and their use
EP1532118A2 (en) * 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
US6972336B2 (en) * 2002-07-18 2005-12-06 Novartis Ag N-alkylation of indole derivatives
EP1539151B1 (en) 2002-08-02 2009-03-18 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
EP1545510A4 (en) * 2002-08-07 2006-11-15 Idenix Cayman Ltd SUBSTITUTED PHENYLINDOLE FOR THE TREATMENT OF HIV
AU2002368154A1 (en) 2002-08-08 2004-02-25 Ribapharm Inc. Improved synthesis for hydroxyalkylated heterocyclic bases
DE10237723A1 (de) 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
WO2004035522A1 (ja) 2002-08-30 2004-04-29 Bf Research Institute, Inc. プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
SE0202692D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
EP1546109A4 (en) * 2002-10-04 2005-11-09 Bristol Myers Squibb Co HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-ALPHA CONVERSION ENZYME (TACE)
US20050215614A1 (en) * 2002-10-15 2005-09-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
WO2004035525A1 (en) 2002-10-17 2004-04-29 Methylgene Inc. Inhibitors of histone deacetylase
MXPA05004128A (es) 2002-10-18 2005-06-22 Hoffmann La Roche 4-piperazinil bencenosulfonil indoles con afinidad al receptor 5-hidroxitriptamina 6 (5-ht6).
WO2004037791A1 (en) 2002-10-21 2004-05-06 Chiron Corporation Inhibitors of glycogen synthase kinase 3
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
WO2004041781A1 (en) 2002-11-07 2004-05-21 Suven Life Sciences Limited Preparation of 3-aminoalkyl-substituted indole derivatives from phenylhydrazines and aminoketones
WO2004041256A2 (en) 2002-11-08 2004-05-21 Novo Nordisk A/S Safe chemical uncouplers for the treatment of obesity
WO2004050035A2 (en) 2002-12-03 2004-06-17 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
EP1457485A1 (en) 2003-03-14 2004-09-15 Dompé S.P.A. Sulfonic acids, their derivatives and pharmaceutical compositions containing them
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0307891D0 (en) * 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
WO2004093912A1 (ja) 2003-04-23 2004-11-04 Kyowa Hakko Kogyo Co. Ltd. 好中球性炎症疾患の予防および／または治療剤
WO2004099192A2 (en) 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
WO2004099170A2 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
EP1620420A2 (en) 2003-04-30 2006-02-01 The Institutes for Pharmaceutical Discovery, LLC Substituted carboxylic acids
JP2006525364A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 置換アミノカルボン酸
DE10320781A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag Acylierte Nonadepsipeptide
GB0313762D0 (en) 2003-06-13 2003-07-23 Biofocus Plc Compound libraries
BRPI0411998A (pt) 2003-06-27 2006-09-05 Janssen Pharmaceutica Nv moduladores delta-opióides tricìclicos
DE10329860A1 (de) 2003-07-02 2005-01-20 Atto-Tec Gmbh Sulfonamidderivate polycyclischer Farbstoffe für analytische Anwendungen
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
ES2222827B1 (es) 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2228268B1 (es) 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222832B1 (es) 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2228267B1 (es) 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
US7696365B2 (en) * 2003-08-01 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
EP1651198A2 (en) 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
KR20060079190A (ko) 2003-08-14 2006-07-05 아사히 가세이 파마 가부시키가이샤 치환 아릴알칸산 유도체 및 그의 용도
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
AU2004268919A1 (en) 2003-09-03 2005-03-10 Galapagos Nv Novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-HT2A receptor-related disorders
WO2005039489A2 (en) 2003-09-24 2005-05-06 Polymerix Corporation Compositions and methods for the inhibition of bone growth and resorption
US7211671B2 (en) * 2003-10-01 2007-05-01 Bristol Myers Squibb Company Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
US7223787B2 (en) * 2003-10-21 2007-05-29 Board Of Regents, The University Of Texas System Prenylation inhibitors reduce host cell permissiveness to viral replication
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
AR046784A1 (es) 2003-12-03 2005-12-21 Glaxo Group Ltd Compuesto de amina ciclica composicion farmaceutica que lo comprende y su uso para preparar esta ultima
US20050123560A1 (en) * 2003-12-04 2005-06-09 Sinnott Robert A. High purity and water dispersible extract and formulations of larrea tridentata leaf resin, and methods of making and using the same
WO2005058315A1 (en) 2003-12-12 2005-06-30 Ribapharm, Inc. Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP4600288B2 (ja) 2003-12-24 2010-12-15 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子用材料、有機エレクトロルミネッセンス素子、照明装置および表示装置
JP2005194198A (ja) 2003-12-26 2005-07-21 Takeda Chem Ind Ltd チエノピリジン化合物
ATE461200T1 (de) 2004-01-08 2010-04-15 Medivir Ab Inhibitoren von cysteinprotease
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2005076861A2 (en) 2004-02-04 2005-08-25 University Of Virginia Patent Foundation Compounds that inhibit hiv particle formation
CN1917870A (zh) 2004-02-11 2007-02-21 Irm责任有限公司 作为lxr调节剂的化合物和组合物
CA2553879C (en) 2004-02-20 2011-02-22 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2005082905A1 (ja) 2004-02-26 2005-09-09 Kyowa Hakko Kogyo Co., Ltd. 二環性複素環化合物
US7371743B2 (en) 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
US20070276020A1 (en) 2004-03-08 2007-11-29 Boykin David W Dicationic Compounds For Activity Against Trichomonas Vaginalis
EP1574502A1 (en) 2004-03-08 2005-09-14 Novartis AG Use of pyrimidine compounds in the preparation of parasiticides
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
BRPI0510717B8 (pt) 2004-05-06 2021-05-25 Bioresponse Llc uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr)
CN1951155A (zh) 2004-05-14 2007-04-18 出光兴产株式会社 有机电致发光器件
DE102004024504A1 (de) 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
AU2005275181A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
CN101068781B (zh) 2004-10-04 2012-02-01 美瑞德生物工程公司 用于阿尔茨海默氏病的化合物
WO2006050236A2 (en) 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
JP2006131519A (ja) 2004-11-04 2006-05-25 Idemitsu Kosan Co Ltd 縮合環含有化合物及びそれを用いた有機エレクトロルミネッセンス素子
EP1829872B1 (en) 2004-11-25 2015-07-29 Nissan Chemical Industries, Ltd. Processes for production of indole compounds
EP1838303B1 (en) 2004-12-30 2011-02-09 Bioresponse LLC Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions

Also Published As

Publication number Publication date
BRPI0511834A (pt) 2008-01-08
US8013006B2 (en) 2011-09-06
WO2006019831A1 (en) 2006-02-23
US20060223863A1 (en) 2006-10-05
ECSP077252A (es) 2007-05-30
EA200700243A1 (ru) 2007-08-31
US20080096928A9 (en) 2008-04-24
KR20070083484A (ko) 2007-08-24
US20120009142A1 (en) 2012-01-12
CA2573185A1 (en) 2006-02-23
EP1771169A1 (en) 2007-04-11
MX2007000481A (es) 2007-03-29
IL180645A0 (en) 2008-04-13
JP2008506702A (ja) 2008-03-06
AU2005275181A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
WO2007025043A3 (en) Seven-membered ring nucleosides
WO2003105770A3 (en) CARBOCYCLIC NUCLEOSIDE DERIVATIVES FOR USE AS VIRAL RNA-DEPENDENT RNA POLYMERASE INHIBITORS
JO2318B1 (en) Nucleoside derivatives used as DNA-based viral RNA inhibitors
WO2004007512A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004000858A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004003138A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
TW200733953A (en) Materials and methods for treating viral infections
NO20070751L (no) Inhibitorer av HCV-replifikasjon
WO2005123087A3 (en) C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
EA200900298A1 (ru) Ингибиторы вируса гепатита с
IL192306A0 (en) Anti-viral compounds
HK1122292A1 (en) Anti-viral compounds
WO2006012078A3 (en) Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
DE60319820D1 (de) Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien
DK2251015T3 (da) Modificerede nukleotider til behandling af virusinfektioner og abnorm celleproliferation
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
ATE505475T1 (de) Nukleosidderivate als inhibitoren viraler polymerasen
DK1644363T3 (da) Triheterocykliske forbindelser, sammensætninger og fremgangsmåder til behandling af cancer eller virussygdomme
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
UY27798A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatits c y composiciones y tratamientos que los usan.
DE602008006257D1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
ATE337309T1 (de) Pyranon- und pyrandioninhibitoren der rna- abhängigen rna-polymerase des hepatitis-c-virus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application